1. India Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Gkb Ophthalmics Limited

Gkb Ophthalmics Limited

57.17
INR
-2.65
(-4.43%)
10.92EPS
9.81P/E
317.56MMarket Cap
Gkb Ophthalmics Limited
BSE:GKB
(Bombay Stock Exchange)

Recent

price

57.17

P/E

ratio

9.81

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
61.1
92.79
102.84
99.8
84.52
105.35
178.36
185.1
123.18
115.68
111.97
140.35
149.54
175.07
216.2
295.7
296.54
Revenue per Share
0.49
7.42
-1.5
9.61
0.01
9.51
6.23
-2.34
-2.38
-3.65
-1.8
2.53
-0.33
-5.58
-13.98
2.42
6.42
Basic EPS, GAAP
-4.29
-4.75
4.15
13.29
15.81
-35.16
-23.41
-10.93
8.44
-1.18
1.04
0.62
-7.91
4.25
-11.06
-9.59
- -
Free Cash Flow per Basic Share
1.45
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
40.06
84.92
84.17
96.06
96.33
107.89
112.64
108.2
118.1
117.55
124.3
125.18
124.38
118.58
103.24
104.82
- -
Book Value per Share
40.06
84.67
83.85
95.78
96.09
107.71
110.75
106.38
116.48
116.06
122.82
125.17
124.37
118.58
103.24
104.45
- -
Tangible Book Value per Share
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
Basic Weighted Avg Shares
254
385
427
415
351
438
741
769
572
583
564
707
754
883
1,090
1,491
1,498
Sales/Revenue/Turnover
-2.31
16.2
5.24
15.45
-3.45
-4.7
1.58
-0.45
-4.19
-2.54
-1.41
3.3
1.18
-2.62
-5.19
3.62
4.66
Operating Margin (%)
8
9
12
12
16
15
14
17
35
36
31
27
28
29
31
32
32
Depreciation Expense
2
31
-6
40
- -
40
26
-10
-11
-18
-9
13
-2
-28
-70
12
32
Net Income, GAAP
79.32
19.98
- -
46.06
- -
49.98
12.12
- -
- -
- -
- -
0.12
16.57
- -
- -
2.47
3.45
Effective Tax Rate (%)
0.8
7.99
-1.45
9.63
0.01
9.03
3.49
-1.26
-1.93
-3.15
-1.61
1.8
-0.22
-3.18
-6.46
0.82
2.17
Profit Margin (%)
126
130
111
133
126
285
295
274
268
314
359
368
424
413
370
368
- -
Working Capital
100
30
25
15
5
1
1
- -
- -
- -
10
16
12
11
31
16
- -
LT Debt
166
353
350
399
400
448
468
449
548
593
663
674
673
642
564
549
- -
Total Equity
0.34
6.76
- -
3.68
- -
6.65
4.08
- -
- -
- -
- -
3.17
1.01
- -
- -
6.79
- -
Return on Invested Capital (%)
1.63
13.07
- -
10.45
- -
9.19
6.62
- -
- -
- -
- -
2.18
0.8
- -
- -
1.73
- -
Return on Capital (%)
1.23
11.87
-1.77
10.66
0.01
9.32
5.65
-2.12
-2.21
-3.23
-1.49
2.03
-0.27
-4.59
-12.6
2.32
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
101
- -
LT Borrowings
- -
16
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
5
5
Market Capitalization
258
265
318

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
1,080
- -
Cash, Cash Equivalents & STI
- -
44
- -
Accounts Receivable, Net
- -
449
- -
Inventories
- -
546
- -
Total Current Liabilities
- -
712
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
101
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.45%
-3.59%
-2.74%
Free Cash Flow
-252.79%
-390.35%
-13.33%
Net Income, GAAP
111.64%
251.74%
-117.3%
Sales/Revenue/Turnover
15.55%
21.85%
36.77%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
260
261
258
310
1,090
2026
323
302
568
298
1,491
2027
330
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.5
-2.41
-4.03
-7.03
-13.98
2026
-2.02
3.17
0.88
0.38
2.42
2027
2
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
GKB Ophthalmics Limited manufactures and sells unfinished ophthalmic lenses, primarily semi-finished organic and mineral lenses including single vision lenses such as 1.498 CR-39, 1.50 Blucheck, 1.56 Blucheck, 1.56 DayNite, 1.56 DayNite Fast Change, 1.50 Q-Shade+, and 1.50 SunSensor; bifocal lenses including 1.498 CR-39, 1.50 Blucheck, 1.56 Blucheck, 1.56 DayNite, 1.56 DayNite Fast Change, and 1.50 Q-Shade+; progressive lenses including 1.498 CR-39, 1.50 Blucheck, 1.56 DayNite, and 1.56 DayNite Fast Change; aspheric lenses including 1.498 CR-39; as well as bifocal glass moulds and other optical products. The company, founded in 1981 and headquartered at 16-A Tivim Industrial Estate, Mapusa, Goa, India, operates as a 100% export-oriented unit with products shipped to various countries worldwide and maintains subsidiaries including GKB Ophthalmics Products FZE in the UAE, GSV Ophthalmics Private Limited in Goa, Prescription Optical Products LLC in Dubai, and step-down subsidiary Lensco in New Jersey, USA. Recent developments include reporting consolidated net sales of Rs 32.31 crore for the quarter ended June 2025, marking the highest quarterly sales in five quarters with a 26.83% growth over nine months to Rs 93.50 crore, alongside a consolidated net profit of Rs 1.60 crore for the quarter ended September 2025 with sales up 15.42% to Rs 30.17 crore; ongoing investments in joint venture GSV Ophthalmics Private Limited for high refractive index lenses with a Korean partner; approval of material related party transactions and increased borrowing limits at the 43rd AGM in August 2025; and operational enhancements evidenced by improved debtors turnover ratio of 4.28 times.